EVEROLIMUS EG 5 mg, tablet 30 tablets
Active ingredients: Everolimus
Commercialized according to BDPMDispensing in France: Prescription only
Tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- EVEROLIMUS EG 5 mg, comprimé
- Pharmaceutical form
- comprimé
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 30 comprimé(s)
- Marketing authorisation holder
- EG LABO - LABORATOIRES EUROGENERICS
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 11 Mar 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62437640CIP73014841CIP133400930148419Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ÉVÉROLIMUScomprimé | 5 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.